CERVICAL NEOPLASMS Clinical Trial
Official title:
A Phase II Trial of Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer Patients
Concurrent chemoradiation (CCRT) is the standard therapy for locally advanced cervical
cancer.
However, the most effective chemotherapy regimen is controversial. Weekly cisplatin,
hydroxyurea + cisplatin, 5-FU + cisplatin are tested in clinical trials.
Weekly cisplatin needs frequent hospital visits and had a poor compliance profile in korea.
Combination chemotherapy regimens had more adverse effects than weekly cisplatin without
improving outcomes.
We conducted a retrospective analysis comparing weekly cisplatin with cisplatin every 3
weeks and observed favorable outcome for cisplatin every 3 weeks regimen (still not
published).
Therefore, we designed a phase 2 trial evaluating the efficacy and feasibility of CCRT with
cisplatin every 3 weeks.
Cervical carcinoma is one of the most common gynecologic cancers worldwide. The prognosis of
cervical cancer is favorable, with an approximately 80-90% 5-year survival rate in
early-stage disease. However, advanced disease carries a poor prognosis.
Current standard treatment for locally advanced cervical cancer, which is not eligible for
surgical treatment, is cisplatin-based concurrent chemoradiation. On the basis of the
results of five randomized clinical trials, which consistently showed improved survival in
patients treated with cisplatin-based chemoradiation, the U.S. National Cancer Institute
(NCI) announced in 1992 that "Strong consideration should be given to the incorporation of
concurrent cisplatin-based chemotherapy with radiotherapy in women who require radiotherapy
for treatment of cervical cancer".
Although recently reported meta-analyses also demonstrated improved local control rates and
survival with cisplatin-based chemotherapy concurrent with radiation, the optimal cisplatin
dose and dosing schedule are still undetermined.
Among the previous five randomized clinical trials, two trials performed by the Gynecologic
Oncology Group (GOG) used weekly cisplatin 40 mg/m2 while the other three trials used
tri-weekly cisplatin at a dosage range of 50 mg/m2 to 75 mg/m2 combined with 5-fluorouracil
(5-FU). Despite the diversity in cisplatin dose and dosing schedules, weekly cisplatin at a
dose of 40 mg/m2 concurrent to RT is widely accepted as the standard regimen of CRT because
of its convenience, equal effectiveness, and favorable toxicity in comparison to other 5-FU
combined regimens.
However weekly cisplatin regimen needs frequent hospital visits and had a poor compliance
profile in korea. With weekly cisplatin regimen, planned treatment was not completed in 58%
patients adn treatment delayed in 29% patient. among these patients, 9% patients were not
related associated toxicities.
To overcome toxicities and poor compliance of weekly regimen, the investigators tried to
evaluate the efficacy and feasibility of CCRT with cisplatin 75mg/m2 every 3 weeks.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02267876 -
Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens
|
||
Enrolling by invitation |
NCT04266093 -
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
|
||
Completed |
NCT01627288 -
Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)
|
N/A | |
Not yet recruiting |
NCT05824494 -
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
|
Phase 2 | |
Recruiting |
NCT04096911 -
Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer
|
Phase 2 | |
Withdrawn |
NCT00950261 -
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
|
Phase 2 | |
Terminated |
NCT00190528 -
A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer
|
Phase 3 |